Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron in Hereditary Hemorrhagic Telangiectasia
NCT00588146Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jan 2007
- Primary completion
- Sep 2011
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in hereditary hemorrhagic telangiectasia (HHT), sponsored by Mayo Clinic. Started Jan 2007; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT00588146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00588146.